Early clinical trials in the UK have shown promising results for a new treatment that effectively resets the immune system in patients with lupus, an autoimmune disease affecting around 50,000 people in the country. This experimental therapy has led to disease remission in most patients treated so far, offering a potential breakthrough for managing lupus and similar conditions.
Lupus primarily affects women, with 90% of cases occurring in young adults. It causes the immune system to mistakenly attack the body's own tissues, resulting in symptoms such as joint pain, skin rashes, and organ damage including to the kidneys. These effects can severely impact quality of life and require ongoing management with medication.
One patient benefiting from the treatment is Katie Tinkler, diagnosed with lupus 30 years ago. Ms Tinkler described how the disease had become aggressive, causing significant organ damage and frequent hospital stays. Before the treatment, tasks as simple as lifting a cup of tea were hampered by pain and stiffness.
Following the experimental therapy delivered at University College London Hospitals in late 2024, Ms Tinkler reports being off all lupus medication and experiencing a dramatic improvement in her health and daily function. "I’ve never been this good," she said, now able to enjoy activities like skiing that were previously impossible.
The treatment employs a form of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy, a technique already approved for certain blood cancers. It involves collecting millions of a patient's own T cells—a type of white blood cell—and genetically modifying them in a lab. These altered T cells are designed to target and destroy B cells, which in lupus become "rogue" and attack the body.
Once infused back into the patient, the modified T cells eliminate both the harmful and normal B cells. After several months, the immune system regrows healthy B cells, effectively "resetting" its function. This approach aims to halt the autoimmune attack at its source rather than merely treating symptoms.
Among six patients treated in this study, five remain in remission after more than 18 months, while one experienced a relapse after 11 months but showed symptom improvement overall. The trial presenters at the European Congress of Rheumatology highlighted these results as an important step forward, though long-term effects and wider applicability require further research.
Dr Maria Leandro, consultant rheumatologist at UCLH, said sustained remission over three to five years would represent significant progress for lupus treatment. Exploring CAR-T therapy’s use in other autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis, is underway. These conditions share similar mechanisms involving errant B cells, making the approach potentially applicable to many patients.
Dr Claire Roddie, leading research on CAR-T therapy at UCL, emphasised the excitement within the medical community about expanding this treatment beyond cancer. Clinical trials for multiple sclerosis are already in progress, aiming to offer better disease control to more patients.
For lupus patients like Katie Tinkler, the treatment represents more than medical advancement; it has restored hope and the possibility of a fuller life. Though the duration of remission remains uncertain, she is making the most of the renewed health, pursuing activities and goals she had put aside.
While this therapy is not yet widely available and carries risks associated with the procedure, its early success offers a new avenue for treating autoimmune diseases that have long vexed patients and clinicians alike. Ongoing trials and monitoring will clarify how broadly and effectively CAR-T therapy can be integrated into lupus care and beyond.
In summary, this developing treatment approach targets the immune system's malfunction at its root, offering a potential shift from symptom management to long-term remission. Patients living with lupus and related autoimmune disorders may see emerging options within the next few years, depending on trial outcomes and regulatory approvals.
